|
1
|
McGlynn KA and London WT: Epidemiology and
natural history of hepatocellular carcinoma. Best Pract Res Clin
Gastroenterol. 19:3–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Azam F and Koulaouzidis A: Hepatitis B
virus and hepatocarcinogenesis. Ann Hepatol. 7:125–129.
2008.PubMed/NCBI
|
|
5
|
Kaihara S, Kiuchi T, Ueda M, Oike F,
Fujimoto Y, Ogawa K, Kozaki K and Tanaka K: Living-donor liver
transplantation for hepatocellular carcinoma. Transplantation. 75(3
Suppl): S37–S40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lopez PM, Villanueva A and Llovet JM:
Systematic review: Evidence-based management of hepatocellular
carcinoma-an updated analysis of randomized controlled trials.
Aliment Pharmacol Ther. 23:1535–1547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakao K, Miyaaki H and Ichikawa T:
Antitumor function of microRNA-122 against hepatocellular
carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gramantieri L, Ferracin M, Fornari F,
Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E,
Grazi GL, et al: Cyclin G1 is a target of miR-122a, a microRNA
frequently down-regulated in human hepatocellular carcinoma. Cancer
Res. 67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin CJ, Gong HY, Tseng HC, Wang WL and Wu
JL: miR-122 targets an anti-apoptotic gene, Bcl-w, in human
hepatocellular carcinoma cell lines. Biochem Biophys Res Commun.
375:315–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Landgraf P, Rusu M, Sheridan R, Sewer A,
Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M,
et al: A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang J, Nicolas E, Marks D, Sander C,
Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, et al:
miR-122, a mammalian liver-specific microRNA, is processed from hcr
mRNA and may downregulate the high affinity cationic amino acid
transporter CAT-1. RNA Biol. 1:106–113. 2004. View Article : Google Scholar
|
|
12
|
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and
Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates
G1/S transition of human hepatocellular carcinoma cells.
Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Reilly LA, Print C, Hausmann G, Moriishi
K, Cory S, Huang DC and Strasser A: Tissue expression and
subcellular localization of the pro-survival molecule Bcl-w. Cell
Death Differ. 8:486–494. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HW, Lee SS, Lee SJ and Um HD: Bcl-w is
expressed in a majority of infiltrative gastric adenocarcinomas and
suppresses the cancer cell death by blocking stress-activated
protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res.
63:1093–1100. 2003.PubMed/NCBI
|
|
15
|
Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS,
Choi KM and Um HD: Bcl-w promotes gastric cancer cell invasion by
inducing matrix metalloproteinase-2 expression via phosphoinositide
3-kinase, Akt and Sp1. Cancer Res. 66:4991–4995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kitamura S, Kondo S, Shinomura Y, Kanayama
S, Miyazaki Y, Kiyohara T, Hiraoka S and Matsuzawa Y: Met/HGF
receptor modulates bcl-w expression and inhibits apoptosis in human
colorectal cancers. Br J Cancer. 83:668–673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gibson L, Holmgreen SP, Huang DC, Bernard
O, Copeland NG, Jenkins NA, Sutherland GR, Baker E, Adams JM and
Cory S: bcl-w, a novel member of the bcl-2 family, promotes cell
survival. Oncogene. 13:665–675. 1996.PubMed/NCBI
|
|
18
|
Ma L, Liu J, Shen J, Liu L, Wu J, Li W,
Luo J, Chen Q and Qian C: Expression of miR-122 mediated by
adenoviral vector induces apoptosis and cell cycle arrest of cancer
cells. Cancer Biol Ther. 9:554–561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu X, Wu S, Tong L, Luan T, Lin L, Lu S,
Zhao W, Ma Q, Liu H and Zhong Z: miR-122 affects the viability and
apoptosis of hepatocellular carcinoma cells. Scand J Gastroenterol.
44:1332–1339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012.PubMed/NCBI
|
|
21
|
Young DD, Connelly CM, Grohmann C and
Deiters A: Small molecule modifiers of microRNA miR-122 function
for the treatment of hepatitis C virus infection and hepatocellular
carcinoma. J Am Chem Soc. 132:7976–7981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martinou JC, Desagher S and Antonsson B:
Cytochrome c release from mitochondria: All or nothing. Nat Cell
Biol. 2:E41–E43. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bai S, Nasser MW, Wang B, Hsu SH, Datta J,
Kutay H, Yadav A, Nuovo G, Kumar P and Ghoshal K: MicroRNA-122
inhibits tumorigenic properties of hepatocellular carcinoma cells
and sensitizes these cells to sorafenib. J Biol Chem.
284:32015–32027. 2009. View Article : Google Scholar : PubMed/NCBI
|
